目的 建立多黏菌素B在重症感染患者中的群体药动学模型，为个体化给药提供科学依据。方法 检索PubMed、Embase、Web of Science、CNKI数据库中关于静脉滴注多黏菌素B的药动学文献，提取多黏菌素B在重症感染患者中的药动学数据，使用Monolix软件建立多黏菌素B的群体药动学模型，并对模型进行图形评价和Bootstrap法验证。结果 多黏菌素B在重症感染患者中的药动学特性符合房室模型，多黏菌素B的清除率（CL）、中央室表观分布容积（V1）、周边室表观分布容积（V2）、隔间清除率（Q）的群体典型值分别为4.36L/h、16.19L、35.14L、0.4L/h，患者的年龄对模型参数Q有显著影响，模型评价表明模型稳定，且有较好的预测效能。结论 本研究建立了重症感染患者多黏菌素B的群体药动学模型，可为多黏菌素B在成年重症感染患者中的个体化用药提供参考。

Objective To develop a population pharmacokinetics model of polymyxin B in patients with severe infection to provide scientific basis for individualized drug administration. Methods The literatures about the pharmacokinetics of polymyxin B were retrieved from PubMed, Embase, Web of Science, CNKI databases, and related pharmacokinetic data were collected from published clinical trials literatures. Then the population pharmacokinetics model of polymyxin B was constructed by Monolix, and the population pharmacokinetics model was validated by pattern evaluation and bootstrap method. Results The population pharmacokinetics characters of polymyxin B were best described by compartment model. The typical population values of CL, V1, V2, Q were 4.36 L/h, 16.19 L, 35.14 L, 0.4 L/h. Age of patients as a covariate affected the Q in this study. Model validation showed that the population pharmacokinetics model of polymyxin B established by this study was reliable and had good predictive performance. Conclusion The population pharmacokinetics model of polymyxin B in patients with severe infection is established successfully and could provide basis for the individualized dosage regimen in adult patients with severe infection.

R978.1

天津市医学重点学科（专科）建设项目资助（TJYXZDXK-032A）；天津医科大学朱宪彝纪念医院院基金（ZXY-YJJ2020-8）